No single governing guideline. Unlike diseases with one dominant framework (e.g. NCCN in oncology), no single cross-disease guideline governs iron-deficiency treatment — guidance is fragmented by context: KDIGO for CKD, ACOG-summarised guidance for pregnancy, ECCO for IBD, ASMBS/TOS for post-bariatric populations. This page does not attempt to reproduce or reconcile those guidelines; consult the guideline governing your specific clinical context.
Key caveats flagged in the data: AEGIS‑H2H (ferric maltol vs IV ferric carboxymaltose) FAILED its primary week‑12 non‑inferiority endpoint (67%/68% vs 84%/85% responders) — the manufacturer's “comparable efficacy” framing applies only to secondary/52‑week data. Imferon (HMW iron dextran) was withdrawn ~1991, a year that is genuinely unresolved across sources (not a precise FDA-documented date); it is distinct from Dexferrum, a later HMW iron dextran discontinued in 2014. Triferic (dialysate, 2015) and Triferic AVNU (IV injection, 2020) are two separate FDA approvals, not one.
Legacy oral salts. Ferrous sulfate, gluconate, and fumarate predate the modern FDA New Drug Application system and are marketed under grandfathered/OTC-monograph status — there is no single, precise "FDA approval year" for these agents. They are represented on the timeline as era anchors rather than point approvals.
Not medical advice. Indication wording, dosing, and trial results are summarised for clinician education; consult current prescribing information, ClinicalTrials.gov, and the guideline governing your clinical context before making treatment decisions.